Revenue grew 2% to $503.9m, but EBIT fell 7% and net profit dropped 20% due to inflation and lower COVID-19 activity. Pharmacy and medical segments saw modest revenue growth but margin pressure, with significant investment in new centres and technology. Cash and net assets declined after large dividend payments.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.